StreetAlpha
13F holdings · Q3 2026

Avidity Partners Management

Dallas, TX · files as Avidity Partners Management LP
Know the moment Avidity Partners Management filesYou follow Avidity Partners Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1791827

Avidity Partners Management reported 17 stocks worth $428M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are DNTH (39.1%), CGON (22.4%) and ORKA (15.3%). Compared with Q2 2026, the fund added to ORKA and JBIO, trimmed DNTH, CGON and CATX and sold out of RGEN, DXCM and TEM.

Latest filing: what Avidity Partners Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
0 new2 added12 trimmed28 sold outBought about $6.3M · sold about $137M
New 0

None

Added 2
Trimmed 12
See all 12 →
Sold out 28
See all 28 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$428M−31.5% vs last quarter · $488M including options
Stocks held170 new · 28 sold out
Top 5 weight89.2%very concentrated
Turnover34%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
DNTH
Dianthus Therapeutics Inc
$167M39.1%1.9M−205K (−10%)8 of 8
2
CGON
CG Oncology Inc
$95.6M22.4%1.3M−50K (−4%)8 of 8
3
ORKA
Oruka Therapeutics Inc
$65.4M15.3%785K+25K (+3%)8 of 8
4
JBIO
Jade Biosciences Inc
$28.1M6.6%2M+299K (+18%)6 of 8
5
ELVN
Enliven Therapeutics Inc
$25.2M5.9%550KNo change7 of 8
6
CATX
Perspective Therapeutics Inc
$16.7M3.9%6.1M−232K (−4%)8 of 8
7
AKTS
Aktis Oncology Inc
$9.4M2.2%484KNo change3 of 8
8
IMUX
Immunic Inc
$6.2M1.5%670KNo change2 of 8
9
MOBI
Mobia Med Inc
$3.1M0.7%325K−474K (−59%)2 of 8
10
PVLA
Palvella Therapeutics Inc NE
$2.8M0.6%20K−50K (−71%)4 of 8
🔒 7 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
RGEN
Repligen Corp
$10.6M78K
TEVA PHARMACEUTICAL INDS LTD
$6.8M200K
DXCM
Dexcom Inc
$6.7M100K
TEM
Tempus AI Inc
$6.1M105K
MDT
Medtronic PLC F
$5.5M70K

🔒 Free account: see all 28.

Options

valued at the underlying shares
StockTypeValueSharesChange
CGON
CG Oncology Inc
Call$60.3M850K+850,000

Reported value

last 8 quarters
$1BQ4 '24
$485MQ1 '25
$499MQ2 '25
$439MQ3 '25
$347MQ4 '25
$936MQ1 '26
$624MQ2 '26
$428MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Avidity Partners Management 13F FAQ

What does Avidity Partners Management own?

Avidity Partners Management reported 17 stocks worth $428M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are DNTH (39.1%), CGON (22.4%) and ORKA (15.3%). The table above lists every position in the filing (the top 10 without an account).

What did Avidity Partners Management buy and sell in Q3 2026?

Compared with Q2 2026: 0 new positions, 2 added to, 12 trimmed and 28 sold out. It sold all of RGEN, DXCM and TEM.

When will Avidity Partners Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Avidity Partners Management's portfolio worth?

The Q3 2026 filing reports $428M in US stocks ($488M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.